^
Association details:
| Biomarker: | TTF1 expression + PD-L1 expression |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
E-PS-21-001 | Pseudoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer – histopathological diagnostic clues
Published date:
08/09/2022
Excerpt:
The patient, a 51-year-old woman...Diagnostic bronchoscopy revealed pulmonary adenocarcinoma with cT4N3M1c, and programmed death-ligand 1 (PD-L1) was expressed in 75 % of the patient’s tumor specimen without any driver mutation. Therefore, only pembrolizumab was administered as the first-line treatment....The pulmonary adenocarcinoma cells showed immuno-expressions of PD-L1 and TTF-1. After one cycle of pembrolizumab, the symptoms improved, and chest radiography showed remarkable remission.
